Loader

Pathways

PathWhiz ID Pathway Meta Data

PW130288

Pw130288 View Pathway
metabolic

Basil Drug Metabolism

Homo sapiens

PW064772

Pw064772 View Pathway
signaling

Basic mechanism of action of PPARa, PPARb(d) and PPARg and effects on gene expression

Homo sapiens
Peroxisome proliferators include hypolipidemic drugs, herbicides, leukotriene antagonists, and plasticizers; this term arises because they induce an increase in the size and number of peroxisomes. Peroxisomes are subcellular organelles found in plants and animals that contain enzymes for respiration and for cholesterol and lipid metabolism. The action of peroxisome proliferators is thought to be mediated via specific receptors, called PPARs, which belong to the steroid hormone receptor superfamily. PPARs affect the expression of target genes involved in cell proliferation, cell differentiation and in immune and inflammation responses. Three closely related subtypes (alpha, beta/delta, and gamma) have been identified. This gene encodes the subtype PPAR-alpha, which is a nuclear transcription factor. Multiple alternatively spliced transcript variants have been described for this gene, although the full-length nature of only two has been determined.

PW130850

Pw130850 View Pathway
metabolic

Basic Fibroblast Growth Factor Drug Metabolism

Homo sapiens

PW146267

Pw146267 View Pathway
drug action

Barium sulfate Drug Metabolism Action Pathway

Homo sapiens

PW146455

Pw146455 View Pathway
drug action

Baricitinib Drug Metabolism Action Pathway

Homo sapiens

PW132428

Pw132428 View Pathway
metabolic

Baricitinib Drug Metabolism

Homo sapiens
Baricitinib is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Baricitinib passes through the liver and is then excreted from the body mainly through the kidney.

PW064796

Pw064796 View Pathway
metabolic

bap

Homo sapiens

PW127628

Pw127628 View Pathway
drug action

Bamlanivimab Action Pathway

Homo sapiens
Bamlanivimab, also known as LY-CoV555 or LY3819253, is a human IgG1K monoclonal antibody (mAb) against the SARS-CoV2 spike protein, called S. This drug was synthesized from the first blood samples of a patient who recovered from COVID-19 in the USA. This molecule is not approved by the FDA, but it is authorized under an Emergency Use Authorization (EUA) for the treatment of COVID-19 patients. X-ray crystallography and cryo-EM structural determination suggest that this molecule binds the receptor-binding domain (RBD) of the spike protein of CoV-19. This binding overlaps the ACE2 binding site. Bamlanivimab is available as an intravenous injection.

PW063839

Pw063839 View Pathway
drug action

Bamipine H1-Antihistamine Action

Homo sapiens
Bamipine is a first-generation piperidine H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.

PW145112

Pw145112 View Pathway
drug action

Balsalazide Drug Metabolism Action Pathway

Homo sapiens